Changes in Renal Function in Patients with Recurrence of Atrial Arrhythmia after an Initial Catheter Ablation
Table 2
Univariate and multivariable Cox regression to identify factors associated with improved renal function in AF patients with mild renal dysfunction after RFCA.
N = 132
HR
95% CI
HR
95% CI
Age (years)
0.98
0.95–1.01
0.269
0.97
0.95–1.00
0.069
Men
0.80
0.51–1.28
0.355
AF type- paroxysmal
1.56
1.00–2.44
0.051
AF duration (months)
1.00
1.00–1.00
0.435
Congestive heart failure
0.77
0.11–5.58
0.799
Hypertension
0.94
0.61–1.46
0.785
Diabetes mellitus
0.88
0.38–2.03
0.765
Stroke
1.08
0.65–1.80
0.755
Coronary artery disease
0.93
0.43–2.02
0.852
Cardiovascular ICD
0.89
0.22–3.63
0.871
Hypertrophic cardiomyopathy
0.05
0.00–320.51
0.500
CHA2DS2-VASc score baseline
0.94
0.78–1.13
0.512
△CHA2DS2-VASc score
0.44
0.25–0.78
0.005
0.42
0.24–0.74
0.003
OAC-warfarin
0.94
0.52–1.69
0.828
OAC-NOACs
0.76
0.43–1.32
0.325
ACEI/ARB
0.92
0.60–1.42
0.700
β-blockers
0.95
0.60–1.49
0.809
CCB
0.70
0.40–1.22
0.204
Diuretics
0.61
0.27–1.41
0.250
eGFR baseline
1.01
0.98–1.04
0.406
LVEF
1.00
0.96–1.05
0.855
LAD
0.95
0.91–0.99
0.017
1.00
0.95–1.05
0.912
LVDd
0.99
0.95–1.03
0.717
Arrhythmia recurrence type- paroxysmal
2.64
1.50–4.62
0.001
2.97
1.60–5.48
0.001
AF, atrial fibrillation; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; OACs, oral anticoagulants; NOACs, nonvitamin K antagonist oral anticoagulants; LAD, left atrium diameter; LVEF, left ventricular ejection fraction; LAD, left atrial diameter; LVDd, left ventricular diastolic diameter; HR, hazard ratio; CI, confidence interval.
